Embecta (NASDAQ:EMBC) Director Milton Mayo Morris Sells 6,293 Shares

Embecta Corp. (NASDAQ:EMBC) Director Milton Mayo Morris sold 6,293 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $5.88, for a total value of $37,002.84. Following the completion of the transaction, the director owned 53,828 shares of the company’s stock, valued at approximately $316,508.64. This represents a 10.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Embecta Stock Down 4.3%

Shares of EMBC traded down $0.25 during mid-day trading on Tuesday, reaching $5.55. 1,361,544 shares of the stock traded hands, compared to its average volume of 1,580,282. The firm has a market cap of $314.46 million, a price-to-earnings ratio of 3.75 and a beta of 0.86. The stock has a fifty day simple moving average of $4.18 and a 200 day simple moving average of $5.80. Embecta Corp. has a 12-month low of $2.77 and a 12-month high of $15.55.

Embecta (NASDAQ:EMBC) last announced its earnings results on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.29. The business had revenue of $271.70 million during the quarter, compared to the consensus estimate of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The business’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, equities research analysts expect that Embecta Corp. will post 1.84 earnings per share for the current fiscal year.

Embecta Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be issued a $0.01 dividend. The ex-dividend date is Thursday, August 27th. This represents a $0.04 dividend on an annualized basis and a yield of 0.7%. Embecta’s payout ratio is currently 2.70%.

Institutional Investors Weigh In On Embecta

A number of institutional investors have recently modified their holdings of EMBC. Larson Financial Group LLC grew its stake in Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares in the last quarter. Wexford Capital LP acquired a new position in Embecta in the third quarter worth $94,000. Tower Research Capital LLC TRC increased its stake in Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after purchasing an additional 6,224 shares during the last quarter. iSAM Funds UK Ltd acquired a new stake in Embecta during the third quarter worth about $115,000. Finally, One Wealth Advisors LLC bought a new position in Embecta in the second quarter worth about $33,000. Institutional investors and hedge funds own 93.83% of the company’s stock.

Wall Street Analysts Forecast Growth

EMBC has been the subject of several recent analyst reports. Bank of America lowered their target price on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research note on Monday, May 18th. Zacks Research upgraded Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Finally, Weiss Ratings downgraded Embecta from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Three equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $11.00.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.